Orexigen Therapeutics Inc (OREX) financial statements (2021 and earlier)
Company profile
| Business Address |
3344 N. TORREY PINES CT. LA JOLLA, CA 92037 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | 9/30/2016 Q3 | 6/30/2016 Q2 | 3/31/2016 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 71 | 87 | 87 | 104 | 76 | 99 | 127 | ||
| Cash and cash equivalents | 46 | 37 | 77 | 92 | 74 | 78 | 68 | ||
| Short-term investments | 25 | 50 | 10 | 11 | 1 | 21 | 59 | ||
| Restricted cash and investments | 40 | 90 | 165 | 165 | 115 | ||||
| Receivables | 19 | 8 | 6 | 1 | 2 | 3 | 3 | ||
| Inventory, net of allowances, customer advances and progress billings | 16 | 16 | 21 | 23 | 24 | 11 | 15 | ||
| Inventory | 16 | 16 | 21 | 23 | 24 | 11 | 15 | ||
| Other undisclosed current assets | 7 | 4 | 5 | 6 | 6 | 4 | 3 | ||
| Total current assets: | 112 | 114 | 159 | 224 | 273 | 283 | 262 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Intangible assets, net (including goodwill) | 70 | 72 | 74 | 76 | 78 | ||||
| Intangible assets, net (excluding goodwill) | 70 | 72 | 74 | 76 | 78 | ||||
| Prepaid expense | 60 | 60 | |||||||
| Restricted cash and investments | 0 | 0 | 0 | 0 | 0 | 0 | 50 | ||
| Other noncurrent assets | 0 | 3 | 3 | 3 | 3 | 1 | 1 | ||
| Total noncurrent assets: | 71 | 76 | 78 | 80 | 83 | 63 | 113 | ||
| TOTAL ASSETS: | 184 | 190 | 236 | 305 | 356 | 345 | 375 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 55 | 39 | 48 | 46 | 41 | 15 | 16 | ||
| Accounts payable | 11 | 8 | 16 | 15 | 12 | 4 | 5 | ||
| Accrued liabilities | 44 | 31 | 32 | 30 | 29 | 11 | 11 | ||
| Business combination, contingent consideration, liability | 15 | 14 | |||||||
| Deferred revenue and credits | 1 | 3 | 2 | 5 | 2 | 10 | 10 | ||
| Other undisclosed current liabilities | 9 | 11 | 5 | ||||||
| Total current liabilities: | 56 | 42 | 49 | 65 | 65 | 35 | 30 | ||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 15 | 15 | 14 | 13 | 13 | 78 | 80 | ||
| Deferred revenue and credits | 7 | 6 | 6 | 6 | 6 | 78 | 80 | ||
| Other liabilities | 0 | 0 | |||||||
| Business combination, contingent consideration, liability | 8 | 9 | 8 | 7 | 6 | ||||
| Total noncurrent liabilities: | 15 | 15 | 14 | 13 | 13 | 78 | 80 | ||
| Total liabilities: | 71 | 57 | 64 | 78 | 78 | 113 | 111 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | (62) | (42) | (8) | 57 | 73 | (10) | 11 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 711 | 707 | 704 | 698 | 696 | 659 | 657 | ||
| Accumulated other comprehensive income (loss) | (7) | (4) | 2 | 4 | (2) | (1) | (3) | ||
| Accumulated deficit | (766) | (745) | (714) | (645) | (621) | (668) | (643) | ||
| Total stockholders' equity: | (62) | (42) | (8) | 57 | 73 | (10) | 11 | ||
| Other undisclosed liabilities and equity | 175 | 175 | 181 | 170 | 204 | 243 | 253 | ||
| TOTAL LIABILITIES AND EQUITY: | 184 | 190 | 236 | 305 | 356 | 345 | 375 | ||
Income statement (P&L) ($ in millions)
| 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | 9/30/2016 Q3 | 6/30/2016 Q2 | 3/31/2016 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 19 | 23 | 19 | 14 | 7 | 8 | 5 | |
| Revenue, net | 19 | 23 | 19 | 14 | 6 | 5 | 3 | |
| Cost of revenue (Cost of Goods and Services Sold) | (4) | (7) | (6) | (4) | (2) | (2) | ||
| Gross profit: | 15 | 17 | 13 | 10 | 5 | 6 | 5 | |
| Operating expenses | (38) | (59) | (67) | 27 | (42) | (39) | (28) | |
| Other undisclosed operating income (loss) | (79) | 79 | ||||||
| Operating income (loss): | (23) | (42) | (54) | (43) | 43 | (33) | (23) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 2 | 11 | (15) | 18 | 5 | 8 | 1 | |
| Interest and debt expense | (1) | (1) | 12 | 24 | (2) | (2) | (2) | |
| Income (loss) from continuing operations before equity method investments, income taxes: | (22) | (31) | (57) | (0) | 46 | (27) | (24) | |
| Other undisclosed loss from continuing operations before income taxes | (18) | |||||||
| Income (loss) from continuing operations before income taxes: | (22) | (31) | (57) | (19) | 46 | (27) | (24) | |
| Other undisclosed loss from continuing operations | (0) | |||||||
| Net income (loss): | (22) | (31) | (57) | (19) | 46 | (27) | (24) | |
| Other undisclosed net income (loss) attributable to parent | 1 | 1 | (12) | (6) | 2 | 2 | 2 | |
| Net income (loss) available to common stockholders, diluted: | (21) | (31) | (69) | (25) | 48 | (25) | (22) | |
Comprehensive Income ($ in millions)
| 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | 9/30/2016 Q3 | 6/30/2016 Q2 | 3/31/2016 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (22) | (31) | (57) | (19) | 46 | (27) | (24) | |
| Comprehensive income (loss): | (22) | (31) | (57) | (19) | 46 | (27) | (24) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (3) | (6) | (14) | (0) | 1 | 4 | (1) | |
| Comprehensive income (loss), net of tax, attributable to parent: | (24) | (37) | (71) | (19) | 47 | (23) | (25) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.